Shane J. Schaffer, PharmD
Chairman, Chief Executive Officer

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is an 18-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions of increasing responsibility at Pfizer, Novartis and Sanofi (including predecessor companies).

Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.

Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.

Raul R. Silva, MD
Chief Science Officer

Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as the CSO. He served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine in New York City. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, also in New York City. Dr. Silva is board certified in general, child and adolescent psychiatry.

Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.

Dr. Silva received his Doctor of Medicine degree from Ross University. He completed his fellowship in child and adolescent psychiatry at Columbia University’s St. Luke’s/Roosevelt Hospital Center where he became the director of service and residency training director. Dr. Silva completed a psychopharmacology research fellowship at New York University Medical Center.

Craig S. Tashjy
Chief Financial Officer

Craig S. Tashjy is a Co-Founder of Cingulate Therapeutics and serves as the CFO. Mr. Tashjy brings 20 years of experience as a financial professional. In addition to the daily management of the firm’s financial operations, Tashjy led the structuring of early-stage funding rounds, provides budget and cash flow oversight, audit and financial reporting and serves as the primary interface with outside accounting and tax partners. In addition, Mr. Tashjy administers the company’s insurance, human resource and employee benefit programs.

Prior, Mr. Tashjy developed multi-platform distribution channels for both domestic and international financial service firms including Morgan Stanley Dean Witter, First Union Brokerage Services and Minnesota Life/Securian Financial Group. Most recently, he led a cross-functional team responsible for a distribution platform with sales in excess of $500M for Old Mutual.

Mr. Tashjy is a graduate of University of Maryland at College Park, attended Whittier Law School and maintains FINRA licensing.

Craig S. Gilgallon, Esq.
General Counsel

Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel. Mr. Gilgallon helped to launch and establish Pawar Gilgallon & Rudy, LLC as well as currently serving as Managing Partner.

Mr. Gilgallon has over ten years of experience in transactional and corporate law. He has a significant amount of leadership and transactional experience with numerous startup companies, and began working with Cingulate Therapeutics in 2012. As general counsel, he directs and manages all aspects of the company’s legal needs and corporate governance.

Mr. Gilgallon received a B.A. from Ithaca College and received his Juris Doctorate from the Thomas Jefferson School of Law.

Matthew Brams, MD

Matthew Brams, MD is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors. Dr. Brams is Medical Director and Principal of Bayou City Research, Inc. There, he has been instrumental in gaining FDA approval of over 15 CNS drugs currently in the marketplace. He has been lead investigator in several pivotal trials involving drugs in ADHD, autism, bipolar disorder and schizophrenia therapeutic areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 125 clinical trials in both adult and pediatric populations in all areas of psychiatry. In addition, he has over 20 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD).

Dr. Brams is a Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine and has published over 20 peer-reviewed journal articles.

He is Board certified in Adult and Child Psychiatry and is a Senior Board Examiner for the American Board of Psychiatry and Neurology.

He earned his MD from the University of Texas Health Science Center in Houston and completed his residencies at Baylor College of Medicine.

Patrick Gallagher, MBA, CFA

Pat Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.

Mr. Gallagher is an accomplished Capital Markets Executive, Advisor, and Investor with a distinguished record of success in both the public and private markets.

He has nearly 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. He is a founding partner and was CEO of BDR Research Group, LLC, a healthcare focused institutional research boutique specialized in providing services for clients in the healthcare investing, financing, and operations areas. Prior, Mr. Gallagher worked for investment and research firms Kidder Peabody, Paine Webber and New Vernon Associates.

Mr. Gallagher currently advises Kinex Pharmaceuticals, a privately held biotech with unique solutions for the treatment of cancer and immunomodulatory diseases, on business development, commercial and financial considerations. He is a co-founder of GCC Partners, a private equity and advisory firm focused on healthcare, energy and industrials.

Laurie Myers, PhD, MBA

Dr. Myers is a pharmaceutical executive, entrepreneur and scientist whose expertise traverses all aspects of branded specialty product life cycle management, from early discovery through product launch, including FDA submissions, P&L responsibilities and creating, disseminating and realizing global marketing plans. Dr. Myers therapeutic expertise includes oncology, cardiovascular disease/thrombosis with additional aptitude in infectious disease, neurologic disease, psychiatric disorders, asthma, urologic disease and women’s health. She has played key roles in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, Aventis, DuPont, Pfizer and Sanofi, which included leadership positions in both R&D and marketing. She has been named to Top 100 Brand Champions by Pharma Voice.

Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and contributes within two investor organizations: Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures. She is a team-focused change agent with a reputation for building strong teams, successfully merging scientific and corporate cultures to optimize high value talent.

Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. Since 2011 she has served as Adjunct Professor at The College of New Jersey School of Business. She currently manages a private consulting company, Hallett Davis Strategic Group, LLC.

Arthur B. Straughn, PharmD

Art Straughn, PharmD is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.

During his 40 years as Professor and Director of the Drug Research Laboratory in the Department of Pharmaceutical Sciences at the College of Pharmacy, University of Tennessee, Dr. Straughn was responsible for the design and conduct of over 200 clinical trials to evaluate drug formulations for effectiveness and safety.

His career has provided him ample opportunity to consult with numerous pharmaceutical companies in helping them develop innovative drug formulations with unique drug delivery properties. More recently he has served as an expert witness in litigations involving patent issues relative to new drug formulations.

Dr. Straughn received his BS in Pharmacy from the University of North Carolina in 1972 and his Doctor of Pharmacy from the University of Tennessee in 1974.